Unaudited financial results of the company for the quarter/half year ended30th September, 2025 along with limited review reports obtained from the Auditor of theCompany.
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts less than Nifty Microcap 250 and 4.9 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indo Us Biotech Limited has submitted its unaudited financial results for the quarter and half year ended 30th September 2025 (Q2/H1 FY26), along with the limited review report from its statutory auditor. This is a routine regulatory filing required under SEBI LODR norms for companies listed on NSE. The limited review report indicates the auditor has performed a review (not full audit) of these interim numbers, as is standard for quarterly results. No specific revenue, profit, or other financial figures, anomalies, or auditor qualifications have been disclosed in the headline of this filing.
This is a routine quarterly compliance filing and is unlikely to move the stock price on its own. Investors should review the actual numbers, segment performance, and any commentary in the limited review report for material insights on the company's growth trajectory, margins, or going concern status.